Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors.

Michalis Liontos Evangelos TerposChristos MarkellosFlora ZagouriAlexandros BriasoulisIoanna KatsianaEfthymia SkafidaOraianthi FisteElena KunadisAngeliki AndrikopoulouMaria KaparelouKonstantinos KoutsoukosMaria GavriatopoulouEfstathios Kastritis Ioannis P TrougakosMeletios-Athanasios Dimopoulos

Published in: Vaccines (2021)

These results suggest that maintaining precautions against COVID-19 is essential for cancer patients and should be taken into consideration for the patients under treatment, while further exploration is needed to reduce the uncertainty of SARS-CoV-2 immunity among cancer patients under treatment.

Keyphrases

sars cov
coronavirus disease
end stage renal disease
respiratory syndrome coronavirus
ejection fraction
newly diagnosed
dna damage
dna repair